Servier to acquire Danish cancer biotech Symphogen
Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.
Move seen as attempt to fend off Takeda takeover
Sales of Protelos hit by safety restrictions.
Companies hope to challenge traiblazers Novartis and Kite.